In the case of RP, the response depends on breast cancer subtype; it is effective in ER+ cell lines but not in those of TNBCs, resembling clinical results (a derivative of RP is used in women with hormone-receptor-positive breast cancer) [13]. Here, NR4A1 is linked to breast cancer.